

11 May 2023

Biologic medicines in Dermatology

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 49
- Adalimumab Biosimilar 185
- Apremilast 6
- Bimekizumab <5
- Brodalumab <5
- Certolizumab <5
- Deucravacitinib <5
- Dimethyl fumarate <5
- Etanercept – Enbrel <5
- Etanercept Biosimilar 9
- Guselkumab 84
- Infliximab – Remicade 5
- Infliximab Biosimilar 7
- Ixekizumab 51
- Risankizumab 79
- Secukinumab 43
- Tildrakizumab 6
- Ustekinumab 77

Q2. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:

- Adalimumab – Humira 21
- Adalimumab Biosimilar 18
- Infliximab – Remicade <5
- Infliximab Biosimilar <5
- Secukinumab <5
- Ustekinumab <5

Q3. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

- Ciclosporin
- Methotrexate - any form and strength
- Methotrexate injections 15mg and above

This data is not available.



11 May 2023

We are unable to provide an exact figure where numbers are very low. This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act as this could make staff personally identifiable. This would be unfair to the individuals to release this information. Disclosure would constitute a breach of the principles of the Data Protection Act 2018.